Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.94 USD | -0.01% | +0.51% | +240.66% |
05-10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
05-09 | Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+240.66% | 4.45B | |
+5.14% | 109B | |
+11.66% | 105B | |
+0.09% | 22.25B | |
-12.12% | 22.09B | |
-7.91% | 18.68B | |
-38.36% | 17.58B | |
-9.54% | 16.85B | |
+4.63% | 13.76B | |
+37.03% | 12.46B |
- Stock Market
- Equities
- ALPN Stock
- News Alpine Immune Sciences, Inc.
- Morgan Stanley Adjusts Price Target on Alpine Immune Sciences to $47 From $30, Maintains Overweight Rating